RLMD Relmada Therapeutics, Inc.
Healthcare$7.17+1.85%ClosedMarket Cap: $525.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.79
P/S
0.00
EV/EBITDA
-8.39
DCF Value
$0.05
FCF Yield
-8.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-71.2%
ROA
-25.0%
ROIC
-27.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-19.5M | $-19.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-20.3M | $-19.9M | $— | — |
| FY null | $0.00 | NaN% | $-59.1M | $-57.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-10.3M | $-10.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.2M | $-9.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-18.2M | $-17.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-19.1M | $-18.7M | $— | — |
| FY null | $0.00 | NaN% | $-83.9M | $-80.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-23.0M | $-21.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-18.8M | $-17.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-23.0M | $-21.8M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-26.8M | $-25.2M | $-0.84 | — |